A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer

BACKGROUND: Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our obje...

Descripción completa

Detalles Bibliográficos
Autores principales: Tsaur, Igor, Heidegger, Isabel, Bektic, Jasmin, Kafka, Mona, van den Bergh, Roderick C. N., Hunting, Jarmo C. B., Thomas, Anita, Brandt, Maximilian P., Höfner, Thomas, Debedde, Eliott, Thibault, Constance, Ermacora, Paola, Zattoni, Fabio, Foti, Silvia, Kretschmer, Alexander, Ploussard, Guillaume, Rodler, Severin, von Amsberg, Gunhild, Tilki, Derya, Surcel, Christian, Rosenzweig, Barak, Gadot, Moran, Gandaglia, Giorgio, Dotzauer, Robert
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446402/
https://www.ncbi.nlm.nih.gov/pubmed/34374489
http://dx.doi.org/10.1002/cam4.4184

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8446402/
https://www.ncbi.nlm.nih.gov/pubmed/34374489
http://dx.doi.org/10.1002/cam4.4184

Ejemplares similares